Loading clinical trials...
Loading clinical trials...
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis
Conditions
Interventions
Upadacitinib (ABT-494)
Locations
18
United States
Beach Pediatrics /ID# 207834
Huntington Beach, California, United States
Children's Hospital Los Angeles /ID# 206042
Los Angeles, California, United States
Pediatric Skin Research, LLC /ID# 213468
Coral Gables, Florida, United States
Rybear, Inc /ID# 231801
Fort Lauderdale, Florida, United States
IACT Health-Columbus /ID# 216370
Columbus, Georgia, United States
Northwestern University Feinberg School of Medicine /ID# 206224
Chicago, Illinois, United States
Start Date
January 31, 2019
Primary Completion Date
August 29, 2024
Completion Date
August 29, 2024
Last Updated
February 10, 2025
NCT07217015
NCT06116526
NCT06461897
NCT07262983
NCT06389136
NCT06342713
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions